Nakamura Yoshiyuki, Kawachi Yasuhiro, Furuta Junichi, Otsuka Fujio
Department of Dermatology, Institute of Clinical Medicine, University of Tsukuba, Ten-nodai, Tsukuba, Ibaraki, Japan.
Eur J Dermatol. 2008 Sep-Oct;18(5):579-82. doi: 10.1684/ejd.2008.0494. Epub 2008 Aug 8.
Severe local skin reactions to subcutaneous injection of interferon beta-1b in multiple sclerosis are rare, and only 12 cases of severe skin reaction due to interferon beta-1b have been reported to date. We report two cases of severe skin reactions in multiple sclerosis patients following the injection of subcutaneous interferon beta-1b. In case 1, after five years of treatment, a painful indurated erythematous lesion appeared at the injection site on the left buttock. On histological analysis, the lesion showed septal and lobular panniculitis with lymphocytic infiltration. In case 2, cutaneous ulceration was surrounded by painful induration, which developed at the injection site on the right thigh after four years of treatment. The lesions resolved rapidly after discontinuation of interferon beta-1b treatment in both cases. Here, we review cases of similar lesions caused by interferon beta-1b reported in the literature, and discuss the characteristics, mechanism, treatment, and prevention of such lesions.
在多发性硬化症患者中，皮下注射β-1b干扰素后出现严重局部皮肤反应的情况较为罕见，迄今为止，仅有12例因β-1b干扰素导致严重皮肤反应的病例报告。我们报告了2例多发性硬化症患者在皮下注射β-1b干扰素后出现严重皮肤反应的病例。病例1，经过5年治疗后，左侧臀部注射部位出现疼痛性硬结红斑病变。组织学分析显示，该病变表现为间隔性和小叶性脂膜炎伴淋巴细胞浸润。病例2，皮肤溃疡被疼痛性硬结包围，在经过4年治疗后于右大腿注射部位出现。在两例病例中，停用β-1b干扰素治疗后病变迅速消退。在此，我们回顾了文献中报道的由β-1b干扰素引起的类似病变病例，并讨论了此类病变的特征、机制、治疗及预防。
